突发性感音神经性聋鼓室内皮质类固醇注射的使用与时机的趋势
该回顾性横断面研究基于2007至2016年美国全国医保索赔数据库,纳入19,670例突发性感音神经性聋患者。结果显示口服皮质类固醇单药使用下降,鼓室内注射单用及联合口服使用上升,且两种给药途径的治疗启动时间均缩短。重复鼓室内注射增多,但可能与持续性鼓膜穿孔风险升高相关。
要点
- 口服皮质类固醇单药治疗比例从83.6%降至64.6%,鼓室内注射单用及联合口服使用均增加。
- 鼓室内注射的治疗启动时间从124.0天缩短至10.6天,口服从42.6天缩短至12.7天。
- 重复鼓室内注射增多,但与持续性鼓膜穿孔风险升高相关(首次注射HR=7.95)。
核心结论
- 突发性感音神经性聋的管理越来越多地采用早期鼓室内注射类固醇作为口服类固醇的替代或辅助方案。
- 重复鼓室内注射皮质类固醇的使用增加,但可能升高持续性鼓膜穿孔及后续鼓室成形术的风险。
研究设计与样本
- 回顾性横断面研究,数据来自2007至2016年IBM Watson Health MarketScan全国医保索赔数据库。
- 共纳入19,670例突发性感音神经性聋患者,采用多因素logistic、线性及Cox回归进行人口学和合并症调整分析。
主要发现
- 口服皮质类固醇单药使用从83.6%降至64.6%(P < .001)。
- 鼓室内注射单用从7.9%升至15.1%(P = .002),鼓室内联合口服从8.5%升至20.4%(P < .001)。
- 鼓室内注射治疗启动时间从124.0天缩短至10.6天(P < .001),口服从42.6天缩短至12.7天(P < .001)。
- 在同时接受鼓室内和口服皮质类固醇的患者中,同期一线使用比例从25.2%升至52.8%(P < .001)。
- 重复注射更常见,持续性鼓膜穿孔风险首次注射HR=7.95(95% CI = 5.54-11.42),第五次或以上注射HR=17.47(95% CI = 6.93-44.05)。
临床怎么用
- 临床中可考虑将早期鼓室内皮质类固醇注射作为突发性感音神经性聋的替代或辅助治疗选项。
- 使用重复鼓室内注射时需权衡持续性鼓膜穿孔及后续鼓室成形术的风险。
- 未来需开展决策分析和成本效果研究以确定突发性感音神经性聋的最佳治疗模式。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Oral corticosteroids are treatment mainstays for idiopathic sudden sensorineural hearing loss (SSNHL). Recent studies suggest that intratympanic (IT) steroid injections may be effective as an alternate or adjunctive therapy. We sought to investigate nationwide trends in treatment patterns for SSNHL. STUDY DESIGN: Retrospective cross-sectional study. SETTING: A large nationwide health care claims database spanning 2007 to 2016. METHODS: Patients with SSNHL were identified from the IBM Watson Health MarketScan Database. Multivariable logistic, linear, and Cox regression were used for demographic- and comorbidity-adjusted analyses. RESULTS: Overall, 19,670 patients were included. Between 2007 and 2016, use of oral corticosteroids alone decreased (83.6% to 64.6%, P < .001), while use of IT corticosteroids alone and combination IT-oral corticosteroids increased (IT only, 7.9% to 15.1%, P = .002; IT-oral, 8.5% to 20.4%, P < .001). During the study period, time to treatment initiation decreased for both administration modalities, though more dramatically for IT corticosteroids (IT, 124.0 to 10.6 days, P < .001; oral, 42.6 to 12.7 days, P < .001). In patients receiving both IT and oral corticosteroids, concurrent first-line use increased (25.2% to 52.8%, P < .001). Repeat injections have also become more common but may raise risk of persistent tympanic membrane perforations (vs no injection; hazard ratio [first injection] = 7.95, 95% CI = 5.54-11.42; hazard ratio [fifth or higher injection] = 17.47, 95% CI = 6.93-44.05). CONCLUSION: SSNHL management increasingly involves early IT steroids as an alternative or adjunctive option to oral steroids. Use of repeat IT corticosteroid injections has also increased but may raise risk of persistent tympanic membrane perforations and subsequent tympanoplasty. Future decision analysis and cost-effectiveness studies are necessary to identify an optimal care pattern for SSNHL.
引用
- Jin MC, Qian ZJ, Cooperman SP, et al. Trends in Use and Timing of Intratympanic Corticosteroid Injections for Sudden Sensorineural Hearing Loss. Otolaryngol Head Neck Surg. 2020. PMID: 33287664. doi:10.1177/0194599820976177
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。